Protective effect of simvastatin on inflammatory factor

Phase 2

Recruiting

• Conditions: N97.8; nexplained female infertility.; Female infertility of other origin

• Registration Number: IRCT20200421047152N3
• Lead Sponsor: Iran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 16 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Female
• Target Recruitment: 84

Inclusion Criteria

Women between 20-40 years old with unexplained infertility
Serum Tumor Necrosis Factor (TNFa) > 5 pg/ml

Exclusion Criteria

History of liver, kidney and muscular diseases
History of metabolic diseases such as diabetes or thyroid dysfunction
History of organic or function genital disorder
History of medication with neurological , cardiovascular and metabolic drugs

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum level of Tumor Necrosis Factor (TNFa). Timepoint: Screening, End of intervention (day 45). Method of measurement: Elisa technique.

Secondary Outcome Measures

Name	Time	Method
Interleukin 1 serum level. Timepoint: Screening, End of intervention (day 45). Method of measurement: Elisa technique.;Humanuman chorionic gonadotropin Beta (ßhCG). Timepoint: Two weeks after embryo transfer. Method of measurement: Elisa technique.;C reactive protein serum level. Timepoint: Screening, End of intervention (day 45). Method of measurement: Immunoturbidimetry.;Clinical Pregnancy. Timepoint: 5 weeks after embryo transfer. Method of measurement: Detection of fetal heart rate (FHR) in trans-vaginal ultrasound.;Adverse Events. Timepoint: During the study period from randomization to the end of the first month after embryo transfer. Method of measurement: Interview and physical examination.